Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19061839 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Shah NP, et al. (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485-93 19061839
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y177-p - Bcr (human)
Orthologous residues
Bcr (human): Y177‑p, Bcr (mouse): Y178‑p, Bcr (rat): Y178‑p
Characterization
 Methods used to characterize site in vivo flow cytometry, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, chronic myelogenous leukemia
 Relevant cell lines - cell types - tissues:  K562 (erythroid), monocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dasatinib decrease inhibition during 20 min treatment, then recovery after washout

Y207-p - CrkL (human)
Orthologous residues
CrkL (human): Y207‑p, CrkL (mouse): Y207‑p, CrkL (rat): Y207‑p
Characterization
 Methods used to characterize site in vivo flow cytometry, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, chronic myelogenous leukemia
 Relevant cell lines - cell types - tissues:  K562 (erythroid), monocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dasatinib inhibit treatment-induced increase transient inhibition at 4ht then recovery
imatinib inhibit treatment-induced increase at concentrations greater than 2.5 uM

Y1069-p - EGFR (human)
Orthologous residues
EGFR (human): Y1069‑p, EGFR iso5 (human): Y1069‑p, EGFR (mouse): Y1069‑p, EGFR (rat): Y1068‑p, EGFR (pig): Y1068‑p
Characterization
 Methods used to characterize site in vivo flow cytometry, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, chronic myelogenous leukemia
 Relevant cell lines - cell types - tissues:  K562 (erythroid), monocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib inhibit treatment-induced increase inhibition during 20 min treatment, then recovery after washout

Y694-p - STAT5A (human)
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
 Methods used to characterize site in vivo flow cytometry, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, chronic myelogenous leukemia
 Relevant cell lines - cell types - tissues:  K562 (erythroid), monocyte
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dasatinib inhibit treatment-induced increase
imatinib inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.